We're continuing to successfully deliver against our ESG commitments, with examples including:
- Supporting comprehensive and diverse clinical trials investigating a twice-yearly injectable for HIV prevention.
- Centering access and removing barriers to care: Our voluntary licensing programs provided access to 14.8 million HIV & HBV treatments and 8.3 million remdesivir-based treatments for COVID-19 in 2024. We also donated over $300 million in 2024 to global programs and partners aligned with our mission,
- Continuing to innovate for unmet needs including a therapy made available in 2024 for primary biliary cholangitis (PBC), a rare liver disease.
- Making significant progress toward ambitious energy reduction targets: surpassing our 2024 energy reduction KPI by 1.1 million kWh and realizing $1.8M in total energy cost savings/avoidance
Impact by the Numbers
14.8M
HIV and HBV treatments made available in 2024
781K
Healthcare providers educated through ¾ÅÓÎÌåÓý’s independent medical education program
271K
People reached with direct HIV services through RADIAN partnership in Eastern Europe and Central Asia since 2019
20M+
HIV and viral hepatitis tests conducted through ¾ÅÓÎÌåÓý’s FOCUS program since 2010
11.7K
Employee volunteer hours in 2024
$300M
Donated globally in 2024
Data updated annually. Next update scheduled for April 2026.